Archive for the ‘Reports’ Category
Novel ‘Antisense’ Therapies Protect Primates from Lethal Ebola and Marburg Viruses
Last Updated on Monday, 30 August 2010 02:01 Written by Editor Monday, 30 August 2010 02:01
ScienceDaily (Aug. 23, 2010) — New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure — suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.
See Also:
Health & Medicine
* Viruses
* HIV and AIDS
* Infectious Diseases
Plants & Animals
* Virology
* Microbes and More
* Monkeys
Reference
* Ebola
* Tropical disease
* Antiviral drug
* Human parainfluenza viruses
The research, which appears in the August 22 online edition of the journal Nature Medicine, was conducted by the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with AVI BioPharma, a Washington-based biotechnology firm.
Working with a class of compounds known as antisense phosphorodiamidate morpholino oligomers, or PMOs, scientists first performed a series of studies with mouse and guinea pig models of Ebola to screen various chemical variations. They arrived at a therapy known as AVI-6002, which demonstrated a survival rate of better than 90 percent in animals treated either pre- or post-exposure.
Encouraged by these results, the team conducted “proof of concept” studies in which 9 rhesus monkeys were challenged with lethal Ebola virus. Treatment was initiated 30-60 minutes after exposure to the virus. In these studies, 5 of 8 monkeys survived, while the remaining animal was untreated. Further experiments, including a multiple-dose evaluation, also yielded promising results, with 3 of 5 monkeys surviving in each of the AVI-6002 treatment groups when they received a dose of 40 mg per kg of body weight.
According to first author Travis K. Warren of USAMRIID, antisense drugs are useful against viral diseases because they are designed to enter cells and eliminate viruses by preventing their replication. The drugs act by blocking critical viral genetic sequences, essentially giving the infected host time to mount an immune response and clear the virus.
Ebola and Marburg cause hemorrhagic fever with case fatality rates as high as 90 percent in humans. The viruses, which are infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), are of concern both as global health threats and as potential agents of biological warfare or terrorism. Currently there are no available vaccines or therapies. Research on both viruses is conducted in Biosafety Level 4, or maximum containment, laboratories, where investigators wear positive-pressure “space suits” and breathe filtered air as they work.
The USAMRIID team next turned its attention to Marburg virus, again screening various compounds in mice and guinea pigs to select a candidate for further testing. They settled upon AVI-6003, a drug that consistently conferred a high degree of efficacy (better than 90 percent survival) in both models.
Investigators conducted two pilot studies in cynomolgus monkeys to assess the efficacy of AVI-6003 against lethal challenge with Marburg virus. As with the Ebola studies, treatments were initiated 30-60 minutes after infection. All 13 animals receiving AVI-6003 survived. Additional research provided important information about the optimal therapeutic dose range of the compound, with a 40 mg per kg body weight dose protecting 100 percent of the monkeys following challenge.
“This report of successful early post-exposure treatment of filovirus hemorrhagic fever is significant on its own,” said Colonel John P. Skvorak, USAMRIID commander, “but the drug characteristics of these PMOs also support investigation of potentially broader therapeutic applications.”
Senior author Sina Bavari said USAMRIID has been collaborating with AVI BioPharma since 2004. In February of that year, an Institute scientist working in a Biosafety Level 4 laboratory stuck her thumb with a needle while treating Ebola-infected mice with antibodies. As a precaution, USAMRIID medical experts recommended the investigator be isolated for 21 days to ensure that she had not been infected.
Coincidentally, earlier that very day, Dr. Patrick Iversen from AVI BioPharma had presented a seminar at USAMRIID concerning the efficacy of novel antisense drugs against a range of viruses. When he found out that a USAMRIID scientist had potentially been exposed to Ebola virus, the company volunteered to design and synthesize compounds against the virus to treat her if the need arose.
The team at AVI worked for four straight days to generate human-grade anti-Ebola compounds. In the meantime, their regulatory staff worked with USAMRIID physicians to gain emergency approval from the U.S. Food and Drug Administration to use the compounds if necessary. Five days after the exposure, AVI delivered the compounds to USAMRIID’s medical team.
Fortunately, the scientist had escaped infection with Ebola virus, so the compounds were never used. However, USAMRIID went on to test them in animal models, and has been collaborating with AVI ever since.
According to the authors, the investigational new drug applications (IND) for AVI-6002 and AVI-6003 have been submitted to the U.S. Food and Drug Administration, and they are now open to proceed with clinical trials.
Collaborating on the study were Travis K. Warren, Jay Wells, Kelly S. Donner, Sean A. Van Tongeren, Nicole L. Garza, Donald K. Nichols, Lian Dong, and Sina Bavari of USAMRIID; Kelly L. Warfield and Dana L. Swenson, formerly of USAMRIID; and Dan V. Mourich, Stacy Crumley, and Patrick L. Iversen of AVI BioPharma.
source: sciencedaily.co
Posted under Clinical Trials, Reports | No Comments
Karwar scientist’s theory to ‘weed’ out CO2
Last Updated on Thursday, 28 January 2010 06:05 Written by Editor Thursday, 28 January 2010 06:05
KARWAR: While representatives of 192 countries are engaged in climate change debates at Copenhagen, Dr Ullas Naik, a marine scientist at the department of marine biology, at Karnatak University’s PG Centre, here has suggested the unassuming sea weed as a possible cure to the planet’s ills.Calling for the scientific culture of algae, commonly known as sea weed and its conservation and protection, Naik points out that these algae provide much of the earth’s oxygen. They absorb carbon dioxide from the environment and carry out photosynthesis to enhance the productivity.Naik, who presented a paper on his findings at a seminar at the university recently, says the discovery has shown that these marine weeds have a remarkable ability to detoxify serious organic pollutants such as TNT or polycyclic aromatic hydrocarbons.According to him, these algae have an intrinsic ability to detoxify TNT 5-10 times faster than any known terrestrial plant.Since some of the marine organisms, particularly marine invertebrates like clamps, shrimp, oyster or crab, the staple food for many, tend to accumulate toxins, growth of sea weeds will have important implications for sea food safety, he asserts.Marine algae contain protein (5- 10%), fat (0.5-1.5%), ash (10-18%), fibre (3-6%) and carbohydrates (40-60%). He says they are rich in minerals and vitamins and can be used as food.The bioactive compound found in seaweeds have variety of applications in pharmaceutical field. Naik says attempts should be made for screening pharmaceutically active compounds from seaweeds. In fact, seaweeds will be the medicinal food of this century, Naik opines.Cautioning that these “wonderful marine species’’ should be explored scientifically, he says they can be used as manure and fodder.
Posted under Press Releases, Reports, Research Projects | No Comments
Rising to the Challenge in R&D
Last Updated on Monday, 11 January 2010 05:22 Written by Editor Monday, 11 January 2010 05:22
Over the past 20 years there has actually been a decline in NMEs approved by FDA. Furthermore, many of the NMEs approved are “me-too†molecules for disease states where first-in-class drugs are already on the market. Granted, there are other reasons for the dearth of product innovation—including regulatory issues, an increasing focus on short-term returns by some shareholders, and corporate restructuring—but the fact remains that pharmaceutical companies need NMEs with novel mechanisms and better safety and efficacy than offered in currently available drugs. Clearly, new chemistry allowing access to well known targets that have been intractable to older chemistries could provide a kick-start to the malaise in drug discovery.
A New Kind of Chemistry: Allosteric Modulation
Even as biologics, RNAi, and gene and cell therapies may provide value to patients in the short-to-medium term, small molecule drugs may one day offer patients many of the same benefits in a format that is more patient friendly (i.e. oral administration) and, potentially, with easier manufacturing and/or lower costs compared to non-pharmaceutical drugs. Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional orthosteric drugs, including biologics.
Allosteric modulators have been shown to achieve greater selectivity, successfully modulating previously intractable therapeutic targets. In addition, orally available small molecule allosteric modulators have been discovered for targets for which only injectable biologic drugs are available. It is easier to achieve selectivity when targeting more heterogeneous allosteric binding sites on targets with therapeutic potential—such as G-Protein Coupled Receptors (GPCRs) and cytokine receptors—than an “active site,†which is often highly conserved across multiple related receptors.
Simply put, the active site on receptors acts as a switch that controls turning receptor signaling. Unlike orthosteric drugs, which turn receptors completely on or off, allosteric modulators act like a dimmer switch to mediate the intensity and frequency of receptor signaling. However, the trigger for signaling remains under the control of the endogenous ligand, which binds the target according to the physiological rhythm determined by the body. In many cases, allowing the body to retain control over initiating signaling while simply increasing or decreasing the amplitude of that signaling may offer a competitive advantage over other approaches. Although it has often been attempted with orthosteric drugs, comparable functional control over receptor signaling cannot be achieved simply by modifying the dose or delivery of orthosteric drugs.
Key Advantages of Allosteric Modulation
- Because they do not compete for the endogenous ligand binding site and exert their effects even in the presence of endogenous ligands, lower doses of allosteric modulators may have greater potency than orthosteric molecules with similar affinity for the same target. Lower dosing often leads to fewer side effects.
- Allosteric modulators can be devoid of activity in the absence of endogenous ligands, offering a less disruptive way to influence the functioning of biological systems and therefore could lead to greater safety and fewer tolerability issues.
- Because they bind on a distinct site, it is possible to create new chemical entities with unfettered intellectual property that re-address well validated GPCR targets for which there are marketed products. In such cases, the goal would be that the allosteric mechanism offer clear differentiation in terms of efficacy and/or side effects.
- It follows that highly selective allosteric modulators can be made for targets where it has been difficult to make selective orthosteric modulators. For example, orally available small molecule allosteric modulators against GLP-1 and FSH receptors—for which only peptide, protein or hormonal therapies are available—have been discovered.
- Because they bind at a separate site, it is possible to combine allosteric modulators with orthosteric drugs. For example, a positive allosteric modulator, or PAM, could be used to potentiate an orthosteric agonist. This could alleviate side effects associated with off-target effects seen at high doses of some orthosteric drugs or simply reduce cost of goods for other orthosteric drugs, especially with biologics.
History of Allosteric Modulators
The concept of allosteric modulation is not new; scientists have been discussing it since the first half of the 20th century, and some suspected such a mechanism even earlier. In the 1960s, Roche introduced the tranquilizer Valium, which later was discovered to act by allosteric modulation of gamma-aminobutyric acid (GABA) receptors. More recent allosteric modulators include Sensipar (cinacalcet, from Amgen), a calcium-sensing receptor PAM, and Selzentry (maraviroc, from Pfizer), a CCR5 NAM.
But these first-to-market drugs were found more through serendipity than through focused searches for allosteric modulators. Indeed, the industrialization of allosteric drug discovery is something that many pharma companies and venture capitalists have shied away from due to the risks and the magnitude of investment.
The search for new drugs has long focused on GPCRs, but of roughly 850 known GPCRs less than 200 have been drugged. Compounds identified through screening have typically worked at the orthosteric site, but after finding the so-called “low hanging fruit,†this approach delivers fewer and fewer hits. In the late 1990s, researchers made some breakthroughs, identifying mGluR selective ligands that didn’t bind to the active sites on glutamate receptors, including allosteric modulators, targeting the metabotropic glutamate receptor 5 (mGluR5), which was discovered by researchers at SIBIA Neurosciences in collaboration with Novartis.
The goal soon became finding similar allosteric drugs; and for this, a new type of screening assay was needed. In the mid-1990s, screening assays evolved to include biological function. When the resulting compounds started to show different types of effects on the receptor, researchers concluded allosteric modulation may be playing a role.
In 2001, Vincent Mutel, CEO of Addex Pharmaceuticals, was a pharmacologist at Roche. Almost by chance, he and his colleagues discovered an allosteric molecule that enhanced the activity of the metabotropic glutamate receptor 1 (mGluR1). This glutamate receptor subtype was not tied to any particular disease, but the finding convinced Mutel that allosteric molecules could enhance an effect as well as block.
Addex was founded in 2002 and initial discovery work focused on targeting mGluR5 for addiction. As mGluRs had been intractable to orthosteric chemistry, Dr. Mutel and his team developed biological screening tools that would detect allosteric modulators of mGluR5 and other mGluR subtypes. It turned out that the tools developed could be adapted to almost any GPCR, and eventually to other types of receptors, like cytokine receptors. GPCRs are the targets of more than 30 percent of all medicines currently on the market . The company has disclosed discovering receptors in all three GPCR families and, more recently advances in the discovery of small molecules targeting receptors such as TNF-R1, IL-1R1, GIPR and GLP-1R, targets that have previously only been addressed by injectable protein or peptide therapeutics .
Future of Allosteric Modulators
The role of specific receptor sub-types has been elucidated in many diseases; however, in many cases, it has been challenging to develop sub-type specific drugs. These cases are the low hanging fruit for allosteric modulators. For example, metabotropic glutamate receptor 5 (mGluR5) has been implicated and clinically or preclinically validated in multiple diseases for more than two decades. But it took Big Pharma more than 20 years after the cloning of the mGluR5 receptor to identify and begin testing selective molecules against this high value target. In the end most if not all the molecules targeting mGluR5 are allosteric modulators. These molecules have progressed into the clinic and are now showing efficacy in humans in a variety of indications.
Addex’s lead compound ADX10059, a negative allosteric modulator of mGluR5, has shown efficacy in separate early Phase II studies for gastroesophageal reflux disease (GERD) and migraines. Clinical and preclinical data from Addex and other groups suggest that the product also has potential in Parkinson’s disease, and certain chronic forms of anxiety and depression. Other companies already are working on mGluR5 inhibitors to treat Parkinson’s disease, Fragile X, and neuropathic pain.
The allosteric drugs also could be combined with conventional orthosteric drugs against the same target to maximize the efficacy of the orthosteric and/or allow use of lower doses. This could be a desirable strategy to minimize dose-related, off-target side effects associated with the orthosteric product while potentially also reducing the cost of goods (especially if it is a biologic).
Allosteric modulators may become a life-cycle management strategy for biologics drugs. In the future, orally available small molecule allosteric modulator may be able to replace or complement many biologic drugs. The cost of a prescription allosteric modulator could, in some cases, obviate the opportunity for bio-generic competition while preserving the profit margin of the prescription biologic.
Allosteric drug discovery and development has only just begun. Many skeptics are being won over and it is beginning to become a mainstream approach. With more than 70,000 potential allosteric modulators in its unique biased library and a growing number of proprietary biological screening tools, Addex is leading the field. Its growing pipeline and partnerships serve as increasingly irrefutable validations. The approach, however, is much bigger than one company, with many in the industry predicting that allosteric modulation will become a new therapeutic class in the medical armamentarium.
Source: findpharma.com
Posted under Drug Development, New Drugs, Press Releases, Reports | No Comments
Agilux Laboratories Hires New Associate Director to Lead In Vitro ADMET Services Division
Last Updated on Thursday, 8 October 2009 12:22 Written by Editor Thursday, 8 October 2009 12:22
- Adrian Sheldon, Ph.D., Positions Contract Research Organization for Growth - WORCESTER, Mass.--(Business Wire)-- Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides bioanalytical and in vitro Absorption Distribution Metabolism Excretion Toxicology (ADMET) services for the biotechnology and pharmaceutical industries, has appointed Dr. Adrian Sheldon as associate director of In Vitro ADMET Services. In this role, Dr. Sheldon will build the In Vitro ADMET Services division offering testing services that allow biotechnology and pharmaceutical companies to screen drug candidates for desirable ADMET properties. Dr. Sheldon will leverage more than 17 years of industry experience, including establishing new business units for In Vitro ADMET and Immunochemistry within an established CRO. He will extend Agilux`s emphasis on customer service, rapid turnaround and exceptional data quality to the company`s newly formed In Vitro ADMET Services Testing Division. "We are excited to have someone with Adrian`s expertise, successful track record and demonstrated abilities at Agilux," said Jim Jersey, president and CEO at Agilux. "Adrian brings the right balance of scientific expertise and customer focus, which is consistent with Agilux`s mission of delivering high quality data at unprecedented speeds. We are confident that both the Agilux team and our clients will benefit from his unique skill set." Prior to Agilux, Dr. Sheldon served as associate director of In Vitro ADMET at Charles River Laboratories. Prior to Charles River Laboratories, Dr. Sheldon was group leader in Assay Development/HTS/In Vitro ADMET at ArQule where he co-managed a team responsible for screening compounds generated by the industry-leading combinatorial chemistry laboratory. He received his Ph.D. from Boston University and his A.B. from Harvard University. Dr. Sheldon has authored numerous scientific publications and holds two patents. "I am very pleased about joining the team at Agilux," stated Dr. Sheldon. "We have an incredible opportunity to change the way early stage development services are delivered and I am confident that I will be able to contribute to Agilux`s continuing success." About Agilux Laboratories, Inc. Agilux Laboratories, Inc. is a privately held contract research organization (CRO) focused on bioanlaytical and PK/PD testing services for the biotech and pharmaceutical industries. Leveraging industry and contract research experience of its management team, the company delivers high quality bioanlaytical chemistry and PK/PD data more rapidly. Agilux helps clients make better decisions during drug discovery and development by providing quality data earlier in the research process by using technologies and systems that increase turnaround speed well beyond industry standards. Founded in 2007 by industry experts Jim Jersey, Steve Guyan and Peter Glick, Agilux is headquartered in Worcester, MA and is funded by private equity firm, Ampersand Ventures. For more information, call 508-753-5000 or email sguyan@agiliuxlabs.com. Online at www.agiluxlabs.com. Agilux Laboratories, Inc. Steve Guyan Vice President, Sales and Marketing 508-762-4402 sguyan@agiluxlabs.com
Source: Reuters
Drug Approvals, Natural And Unnatural
Last Updated on Friday, 21 August 2009 01:16 Written by Editor Friday, 21 August 2009 01:16
I seem to have been putting a lot of graphics up this week, so here’s another one. This is borrowed from a recent Science paper on the future of natural-products based drug discovery. It’s interesting both from that viewpoint, and because of the general approval numbers:
And there you have it. Outside of anomalies like 2005, we can say, I think, that the 1980s were a comparative Golden Age of Drug Approvals, that the 1990s held their own but did not reach the earlier heights, and that since 2000 the trend has been dire. If you want some numbers to confirm your intuitions, you can just refer back to this.
As far as natural products go, from what I can see, the percentage of drugs derived from them has remained roughly constant: about half. Looking at the current clinical trial environment, though, the authors see this as likely to decline, and wonder if this is justified or not. They blame two broad factors, one of them being the prevailing drug discovery culture:
The double-digit yearly sales growth that drug companies typically enjoyed until about 10 years ago has led to unrealistically high expectations by their shareholders and great pressure to produce “blockbuster drugs” with more than $1 billion in annual sales (3). In the blockbuster model, a few drugs make the bulk of the profit. For example, eight products accounted for 58% of Pfizer’s annual worldwide sales of $44 billion in 2007.
As an aside, I understand the problems with swinging for the fences all the time, but I don’t see the Pfizer situation above as anything anomalous. That’s a power-law distribution, and sales figures are exactly where you’d expect to see such a thing. A large drug company with its revenues evenly divided out among a group of compounds would be the exception, wouldn’t it?
The other factor that they say has been holding things back is the difficulty of screening and working with many natural products, especially now that we’ve found many of the obvious candidates. A lot of hits from cultures and extracts are due to compounds that you already know about. The authors suggest that new screening approaches could get around this problem, as well as extending the hunt to organisms that don’t respond well to traditional culture techniques.
None of these sound like they’re going to fix things in the near term, but I don’t think that the industry as a whole has any near-term fixes. But since the same techniques used to isolate and work with tricky natural product structures will be able to help out in other areas, too, I wish the people working on them luck.
Posted under Business and Investment, Drug Development, R & D, Reports | No Comments
Biological Drugs Spurring an Evolution in Injectable Drug Delivery
Last Updated on Thursday, 3 January 2008 07:48 Written by admin Thursday, 3 January 2008 07:48
(Amherst, NH) – The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and – ultimately – pharmaceutical marketers.
Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.
Compliance with drug therapy and disease management protocols has been and is a primary concern within the healthcare and pharmaceutical industries. Efforts to enhance compliance are having a non-negligible effect on drug formulations and delivery decisions, and can be a significant factor in the prescribing decisions of most physicians. Compliance concerns have driven and continue to drive investment in new drug delivery technologies.
As patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that new drug product success no longer only depends on the medication itself but also on achieving a patient-friendly form of application.
New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Reusable injectors designed to accept prefilled syringes or drug cartridges will improve ease-of-use and increase alternative device share of the growing self-injection market. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.
These findings are contained in a comprehensive report, Injectable Drug Delivery: Evolving Markets, Emerging Opportunities. More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Drug Patents expire in June 2007 (Tradename
Last Updated on Wednesday, 13 June 2007 02:49 Written by admin Wednesday, 6 June 2007 09:33
These drug patents will expire in June 2007
Drug Tradename Applicant Company Generic Drug Name Patent Number Patent Expiration
————————————————————————————————–
AEROBID Roche Palo flunisolide 4,933,168 JUN 12,2007
ANTHELIOS SX Loreal Usa avobenzone; ecamsule; octocrylene 4,585,597 JUN 16,2007
ESTRING Pharmacia And Upjohn estradiol 4,871,543 JUN 12,2007
ESTRING Pharmacia And Upjohn estradiol 5,188,835 JUN 12,2007
IMITREX Glaxosmithkline sumatriptan 4,816,470 JUN 28,2007
IMITREX Glaxosmithkline sumatriptan succinate 4,816,470 JUN 28,2007
IMITREX STATDOSE Glaxosmithkline sumatriptan succinate 4,816,470 JUN 28,2007
LAMISIL Novartis terbinafine 4,755,534 JUN 30,2007
LAMISIL Novartis terbinafine hydrochloride 4,755,534 JUN 30,2007
LAMISIL AT Novartis terbinafine hydrochloride 4,755,534 JUN 30,2007
MAVIK Abbott trandolapril 4,933,361 JUN 12,2007
NASALIDE Ivax Res flunisolide 4,933,168 JUN 12,2007
NASAREL Ivax Res flunisolide 4,933,168 JUN 12,2007
PAXIL Glaxosmithkline paroxetine hydrochloride 4,721,723 JUN 29,2007
PAXIL CR Glaxosmithkline paroxetine hydrochloride 4,721,723 JUN 29,2007
PHOTOFRIN Axcan Scandipharm porfimer sodium 4,932,934 JUN 12,2007
TARKA Abbott trandolapril; verapamil hydrochloride 4,933,361 JUN 12,2007
THALITONE Monarch Pharms chlorthalidone 4,933,360 JUN 12,2007
VERELAN Elan Drug verapamil hydrochloride 4,863,742 JUN 19,2007
VERELAN PM Elan Drug verapamil hydrochloride 4,863,742 JUN 19,2007
Source: DrugPatentWatch.com
Posted under Discoveries, Innovations and Patents, Europe, North America, Reports | No Comments
The imminent change of the antithrombotics market
Last Updated on Wednesday, 30 May 2007 02:02 Written by admin Wednesday, 30 May 2007 02:02
The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio
Barcelona, Spain | May 30, 2007 | The Business Intelligence firm La Merie S.L. reported today that the US$ 9.6 bln market of the two blockbuster antithrombotic agents enoxaparin and clopidogrel is going to be rearranged by loss of patent protection and emergence of phase III stage competitors with improved profiles. While Bristol-Myers Squibb already suffers from dropping sales (US$ 3.3 bln in 2006 for clopidogrel), Sanofi-Aventis will be affected stronger in its ex-US sales of clopidogrel (US$ 3 bln) and global sales of enoxaparin (3.3 bln). Sanofi-Aventis has the biggest anticoagulant pipeline by numbers, but does not lead the next generation of oral thrombin (factor IIa) and factor Xa inhibitors which have the potential to replace parenteral product enoxaparin, a low molecular weight heparin (LMWH). At least seven clinical stage direct thrombin inhibitors and at least 10 clinical stage direct factor Xa inhibitors are in the anticoagulant pipeline lead by Boehringer Ingelheim and Bayer Schering Pharma. Despite the larger market of the antiplatelet agent prasugrel, the number of advanced clinical stage antiplatelet projects is smaller than that of anticoagulants. These results and more were found in a competitor analysis conducted by La Merie Business Intelligence. The competitor analysis of Antithrombotics can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.
The competitor analysis evaluated anticoagulant and antiplatelet agents in development. Apart from the oral direct factor IIa and Xa inhibitors, oral heparin and oral LMWH developments are ongoing and novel targets being explored in preclinical and clinical trials. Further companies with a strong antithrombotics portfolio include Daiichi-Sankyo, AstraZeneca and Organon & Schering-Plough. The convenience of oral administration will be the most obvious advante of the next generation anticoagulants, but the reduced incidence of thrombotic events and of bleeding side effects key to the commercial success under the light of the imminent approval of the first enoxaparin generics.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
About PipelineReview.com
Pipelinereview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. A free R&D Newletter conveniently brings via e-mail a daily selection of the most interesting news from biopharmaceutical R&D. For more information visit pipelinereview.com
Posted under Business and Investment, Europe, Press Releases, Reports | No Comments
A Promising Future? Pharmaprojects Reveals an Increase in Drug R&D for 2007
Last Updated on Monday, 7 May 2007 02:17 Written by admin Monday, 7 May 2007 02:17
LONDON, May 1 /PRNewswire/ — Pharmaprojects, the world’s leading source of business-critical intelligence on drugs in global R&D reveals that after a period of levelling off in recent years in the growth of the number of drugs in development, a new era of pipeline expansion may have begun. Pharmaprojects’ unique ‘Trends Search’ facility, which recently published its new data for 2007, shows a palpable increase in the number of drugs in R&D this year (see Graph 1 above)
As the above graph shows, there had been a period from 2004-2006 of relatively slow growth in the number of drug candidates being pursued, when compared to significant increases seen in the early part of the decade. There had been fears in some sectors that this lack of growth might have signalled a permanent change in the pharmaceutical industry’s fortunes and could even have signified a point at which growth might go into reverse. Hopefully however, this newest figure could represent the beginning of a brighter phase.
Pharmaprojects’ data shows that at this time last year there were just less than 400 fewer products under development within the industry, which considering the cost of bringing drugs through the development process, represents an increased investment of many millions of pounds. Pharmaprojects’ trends search also allows one to drill down into this information further and assess how this overall increase in drug development is reflected in the various stages of the R&D process (see Graph 2 above)
Perhaps the most encouraging result of this further analysis is that this increase is not ascribable to a large rise in the number of preclinical compounds, as is often the case, but that the largest increases are in the clinical stages of drug development. As preclinical compounds stand a relatively low chance of making it to the market, a larger increase here does not necessarily represent a particularly positive trend. However, once a compound makes it past the screening process to enter clinical trials, the possibility of it successfully reaching the market increases dramatically with each further stage achieved.
On a more cautionary note, one should remember not to jump the gun with such analyses. As Ian Lloyd, Managing Editor of Pharmaprojects, states, “One year’s worth of promising data does not mean an end to the industry’s woes. Trends by their very nature only emerge after a number of years, making next year’s figures crucial in determining whether we are seeing a sustained recovery or whether 2007 is merely a blip”. Nonetheless, any positive trend must begin somewhere, and this year’s data makes for encouraging reading indeed.
About Pharmaprojects
Pharmaprojects, the leading database tracking global pharmaceutical development from early preclinical study through to launch or discontinuation, has 27 years’ experience as an information provider to the industry. Pharmaprojects uses a fully-searchable application that allows you to pinpoint the specific information you are looking for, whether it be comprehensive drug profiles, a competitor’s pipeline or licensing opportunities.
About Pharmaprojects’ Trend Analysis
Pharmaprojects provides the unique and unparalleled ability to view trends in the pharmaceutical industry by taking a ‘snapshot’ of the database every year since 1995, allowing subscribers to compare year-on-year data across a variety of searchable criteria including drug status, originators, countries, therapies, pharmacologies and more. All data and diagrams contained within this press release are taken directly from Pharmaprojects.
Pharmaprojects is available weekly on the Web and monthly via CD-ROM format. Further details on this story as well as a wealth of information including recent conferences, companies and drug targets are all available in Pharmaprojects’ Update Analysis newsletter. This, as well as a forum of other free information regarding pharmaceutical R&D pipeline intelligence and demo requests for Pharmaprojects, can be found at http://www.pharmaprojects.com
Posted under Business and Investment, Europe, Press Releases, Reports | No Comments
Proprietary Formulation Technologies Advancing in Preclinical Drug Development
Last Updated on Wednesday, 2 May 2007 07:12 Written by admin Friday, 6 April 2007 04:07
New Report by Applied Data Research Analyzes the Impact on Drug Development Timelines
(Nashua, NH) – As the availability of new tools for automating the drug discovery process identifies potential drug candidates at an accelerating rate, the formulation limitations of a majority of these new NCEs is creating a bottleneck in preclinical development. Drug developers are responding by exploring drug formulation technologies – often proprietary processes offered by third parties – to negotiate their way past critical steps in the path to commercializing new chemical entities and driving the financial success of their companies.
Much of the current focus in formulation science is concerned with processes that can improve the solubility of APIs. The importance of solubilization technologies is also underscored by the capability they bestow on formulators attempting to re-formulate approved drugs approaching the end of their patent life.
Issues surrounding water insolubility of active compounds have important business and market implications for new drug development. This impact goes beyond potential future drug therapeutics, effectively limiting reformulation strategies for existing products at a time when extending the market life of proprietary drugs through derivative formulations has become a key business strategy.
Drug formulation technology companies are working with drug developers at pharmaceutical companies to help define the prescription formulations that will enter preclinical development and the clinical trial pipeline in the coming months and years. New formulation capabilities will expand the number of new NCEs that can be formulated to meet pharmacochemical thresholds.
More information is available at www.applieddata.org .
About Applied Data
Applied Data Research is a drug therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Contact:
Greg Stone
Voice: 603-595-6225
Fax: 603-804-0466
www.applieddata.org
Source: Applied Data Research
Posted under Compound Libraries, Drug-Like Compounds, North America, Press Releases, Reports | No Comments
Examine Major Patents Issued in the Last Two Years to the World’s Cell Based Screening & Analysis Industry
Last Updated on Thursday, 1 February 2007 06:58 Written by admin Thursday, 1 February 2007 06:58
DUBLIN, Ireland–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/reports/c48935 ) has announced the addition of Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery to their offering.
This report reviews, analyzes and sizes the cell based screening and analysis market. The study uncovers interesting information about key equipment, consumables, reagents, software and services that are marketed to biotech and pharmaceutical companies that are doing drug discovery research.
Large bio-pharma companies have commented at industry meetings that fifty percent of their high throughput compound screening projects in drug discovery involves screening cells. The companies are using cell-based assays for both primary and secondary screening and have taken a great interest in the areas of high content screening and high content analysis.
The report assesses the market and maps the competitors on the market landscape with more than 80 companies identified. The financial section sizes the market and discusses the five-year revenue projection. The market is segmented by major product areas as well as market sub segments. This market is also segmented by major world regions to see the growth or how the market share might change.
Major company alliances, M&As, patents that were issued during the last two years are reviewed and analyzed. Large data tables summarize the alliances, M&As and patents. The alliance table summarizes more than 210 deals. The patent table displays key details of over 340 patents.
This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. More than 42 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like.
This report includes 28 company profiles that provide the reader a snapshot of the companies’ focus or activities. The provided Internet links help readers access companies’ own web sites for further review.
Topics Covered 1. What Cell Analysis is and What We Are Aiming for With This Research Project 1.1 Our Definition of the Cell Analysis Market 1.2 The Aim of This Research Report 2. Overview -- Current Market Status and R&D Status in Biotech and Pharma (Bio-Pharma) for Cell Analysis 2.1 Cell Based Screening & Analysis Helps Pharma Productivity 2.1.1 Drug Making Productivity 2.1.2 Increasing Use of Cell Based Screening and Analysis Platforms 2.2 Cell-Based Analysis Applications in Bio-Pharma Drug Discovery & Development 2.2.1 Traditional Pharma Drug Discovery Paradigm & Compound Screening 2.2.2 Drug Targets and Main Drug Target Classes 2.2.3 Cell Assay Development - Bio-pharmas Make Their Own Assays 2.2.4 High Throughput Screening (HTS) & High Content Screening (HCS) 2.2.5 Toxicology Testing (Safety Screening) 2.3 Current Equipment & Tools and R&D for Cell Analysis 2.4 Current Technologies and Related R&D for Cell Based Screening-Analysis 2.5 Current Reagents & Assays and Related R&D for Cell Based Screening-Analysis 2.6 Main Competitors by Large, Medium and Start-up (Emerging Companies) 3. Trends and Directions of Cell Based Screening and Analysis Equipment and Technologies 3.1 Trends: Cell Screening Equipment 3.1.1 Plate Imaging Equipment for Cell based HTS 3.1.2 Imaging Cytometry Equipment for HCS/ HCA 3.1.3 Emerging Developments In Cell Based Screening 3.2 Trends: Cell Screening Technologies 3.2.1 Labeling Reagents and No-Wash Assays 3.2.2 Cells as Reagents 3.2.3 Stem Cells Used as a Drug Discovery Tool 4. Alliances & IP 4.1 Summary and Review of Major M&As, Alliances, or Deals 4.1.1 M&A and Alliances at a Glance 4.1.2 Leading M&A Acquirers 4.1.3 Data Tables for M&As and Alliances Involving Cell-Based Analysis 4.2 Summary of Key Patent IP Involving Cell-Based Analysis 5. Market Size and Forecast 2006 to 2011 5.1 The Total Worldwide Cell-Based Screening-Analysis Market Size 5.2 Market Segments by Product Type and Revenues 5.2.1 Major Market Segments by Main Product Areas 5.2.2 Comparison of Major Market Segments by Market Shares, 2007& 2011 5.2.3 Equipment Segment by Product Type 5.2.4 'Consumables' Segment by Product Type 5.2.5 Content Segment by Product Type 5.2.6 Services Segment by Product Type 5.2.7 'Others' Segment by Product Type 5.3 Market Segments By Major Worldwide Regions 5.3.1 Region Segments 5.3.2 Comparison of Region Segments by Market Shares, 2007 & 2011 5.4 Outlook for Leading Commercial Vendors Market Share Rank 6. Activities of Cell Based Screening-Analysis Companies 6.1 Multiplatform Cell Screening/Analysis Systems 6.1.1 to 6.1.7 Total 7 companies 6.2 Flow Cytometry Screening Systems 6.2.1 to 6.2.4 Total 4 companies 6.3 High Content Screening/Analysis Cell Imaging Systems 6.3.1 to 6.3.5 Total 5 companies 6.4 Cell-Based Screening Assays/Reagents 6.4.1 to 6.4.5 Total 5 companies 6.5 Cell Screening Assays/Reagents 6.5.1 to 6.5.3 Total 3 companies 6.6 Contract Research and Development Services 6.6.1 to 6.6.3 Total 3 companies 6.7 Cell Screening/Analysis Software 6.7.1 to 6.7.4 Total 4 companies 7. Conclusions: Findings & Opportunities 7.1 Important Findings 7.1.1 Market Size and Growth 7.1.2 Alliances and IP 7.1.3 Bio-Pharma Product & Technology Users 7.1.4 Equipment 7.1.5 Services 7.2 The Cell-Based Screening & Analysis Business/ Tech Market Roadmap and Opportunities 7.2.1 Major CBSA Products & Services Segments by Growth Rate 7.2.2 Important Growth Areas Within Major Segments 8. Appendix 8.1 Company Contacts (Total 85 companies) 8.2 Patent Data Tables (Total 340 patents)
List of Tables
List of Illustrations
For more information visit http://www.researchandmarkets.com/reports/c48935
Posted under Business and Investment, Europe, Press Releases, Reports | No Comments
Discussion on the Basics of Bird Flu and its Influence on Society on a Whole
Last Updated on Sunday, 27 August 2006 08:40 Written by admin Sunday, 27 August 2006 08:40
DUBLIN, Ireland–(BUSINESS WIRE)–Aug 24, 2006 – Research and Markets (http://www.researchandmarkets.com/reports/c41023) has announced the addition of Avian Influenza: The Threatening Pandemic to their offering.
The purpose of this report is to describe the threatening world pandemic caused by avian influenza, also known as bird flu. This report discusses the origins of the disease, the bird-to-human infection risks, the catastrophic health crisis avian flu poses, and the efforts by world governments and international health organizations to mitigate the impact of the threat to humans.
Chapter Titles Include:
1. Overview
2. Introduction and Executive Summary
3. The Basics of Human Influenza
4. The Basics of Avian Influenza
5. Epidemiology of Avian Influenza
6. Influenza Diagnosis & Laboratory Issues
7. Preparedness
8. Economics of Avian Influenza
9. Fighting the Flu
List of Tables
For more information visit http://www.researchandmarkets.com/reports/c41023
Contact Research and Markets Laura Wood Fax: +353 1 4100 980 press@researchandmarkets.com
Posted under Bird Flu Research, Europe, Press Releases, Reports | No Comments
New Stem Cells Market Report Released
Last Updated on Friday, 19 May 2006 11:15 Written by admin Friday, 19 May 2006 11:15
The Stem Cells space is one of the hottest Areas in Biotechnology, yet it's an Uncharted Terrain, with Significant Opportunity. This new industry report from Select Biosciences provides an up-to-date overview and analysis of technology, business, regulatory trends and key company profiles. In this report, Select Biosciences presents an analysis of the stem cell landscape as it is maturing and evolving. A thorough overview of the biology of stem cells is provided, together with analyses of the funding trends, intellectual property, market opportunity, emerging areas of application, therapeutic pipeline and key centers for stem cell research worldwide. Furthermore, in this report qualitative and quantitative market analysis of the stem cells space is presented. Also presented is the potential market opportunity, and the various qualitative and quantitative drivers that are contributing to the growth of this marketplace. Key Highlights of this report: * Funding Trends in the US and Worldwide * Therapeutic Areas where Stem Cells are expected to have an impact, together with the clinical pipeline of therapeutic entities * Qualitative and quantitative market analyses * Segmentation of the Stem Cells marketplace * Qualitative market drivers * Quantitative market analysis * Intellectual Property (IP) landscape * Emerging market segments For more details visit http://selectbiosciences.com/marketreports/stemcells2006.aspx About Select Biosciences www.SelectBiosciences.com Select Biosciences Ltd. is a publisher of market reports and an organizer of specialist biomedical meetings and training courses. For further information on this report, contact: Kathy Gray, Kathy.gray@selectbiosciences.com
Posted under Press Releases, Reports | No Comments
Therapeutic Opportunities for Dry Powder Inhalation Accelerating
Last Updated on Monday, 13 March 2006 05:08 Written by admin Monday, 13 March 2006 05:07
Greystone Associates Analyzes Technology and Therapeutic Factors
(Amherst, NH) – The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative inhaler device designs – is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, a new survey reveals the emerging developments and market dynamics that have positioned dry powder inhalation as the technology of choice for an increasing number of therapeutic drugs.
The survey concludes that the rising potential of dry powder inhalation is being driven by escalating research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. “The combination of improved particle properties and more efficient inhaler designs is creating new opportunities for dry powder inhalation and expanding the range of active compounds that can be effectively delivered via the lungâ€, explains George Perros, Greystone’s Managing Director. “We believe dry powder inhalation will become a major factor in the delivery of a number of emerging therapeutics.â€
These findings are contained in a new and comprehensive report: Dry Powder Inhalation: Drugs, Devices, And Delivery Therapeutics. It includes comprehensive assessments of dry powder inhalation technology, profiles of dry powder inhalation market participants, industry data and forecasts, and detailed analysis of design and economic factors.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org Source: Greystone Associates
Posted under Press Releases, Reports | No Comments
Microplate Instrument Trends
Last Updated on Thursday, 15 December 2005 02:41 Written by admin Thursday, 15 December 2005 02:41
This market report summarizes the results of a comprehensive global Pharma/Biotech web-based survey on microplate instrumentation trends carried out in May 2005. The main survey looked at the factors that currently limit productivity from a microplate instrumentation perspective; current and future use of microplate detection instruments and microplate readouts; liquid handling for bulk reagent dispensing and sample addition; difficulty in enabling liquid handling applications and reliability of dispensing; current and future use of microplate washers and washing applications; comparative vendor use and respondent ratings; use of different microplate formats and total assay volumes; data point metrics; and microplate instrument budgets and breakdown.
Posted under Equipment & Supplies, Europe, Reports | No Comments
Xceleron and Servier Sign Collaborative Agreement to Accelerate Drug Development Using Microdosing
Last Updated on Thursday, 8 December 2005 05:28 Written by admin Wednesday, 7 December 2005 05:19
YORK, Scotland, December 7, 2005 – Xceleron, the bioanalytical CRO who has pioneered human Phase 0 microdose studies and Servier, a French pharma company, announce today that they have signed a twelve-month rolling Collaborative Agreement. The Agreement covers the provision by Xceleron of accelerator mass spectrometry (AMS) services to assist Servier in taking candidate drugs into humans much earlier than conventional Phase 1 studies. This Agreement is the first of its kind whereby a pharma company is altering its traditional discovery/development processes to accommodate early human studies as part of the drug candidate selection processes.
Professor Colin Garner, Xceleron’s CEO commented “this collaborative Agreement is the result of Servier and Xceleron working together for a number of years to use the AMS technology to accelerate drug development. It shows the far-sightedness of Servier in introducing novel enabling technologies to change their paradigm of drug development”. Dr Bernard Marchand, Servier’s Director of Biopharmacy commented, “we are delighted to be working with Xceleron who have pioneered the human Phase 0 microdose approach. Our positive experience as one of the supporters of the CREAM trial has enabled us to see the potential utility of AMS in improving our drug selection procedures”.
-Ends-
Notes to Editors
About Xceleron Ltd Xceleron is the world’s leading commercial biomedical AMS Company. With two locations in the UK and one in the USA, Xceleron is a GLP accredited organisation with unique expertise in its field of ultrasensitive analysis of drugs and their metabolites. Xceleron’s technology has been used to assist 15 of the world’s top 20 pharma companies in their drug development activities.
As many as one in three drugs fail in Phase I (healthy volunteer) clinical testing despite extensive pre-clinical screening of potential clinical candidates with a wide variety of in silico, in vitro, ex-vivo and animal models. A high proportion of these failures can be attributed to sub-optimal pharmacokinetics (PK) leading to potential efficacy or safety issues in humans.
There is general recognition by the pharma industry that more clinical information needs to be gathered earlier than currently practiced. The AMS technology permits (1) Phase I / mass balance studies to be combined (2) absolute bioavailability studies to be conducted with less animal safety testing (3) early human metabolite profiling and (4) human microdosing (Phase 0 studies) as an aid in candidate selection. All these approaches allow earlier entry into humans of new drug compounds and hence assist in reducing attrition rates later down the clinical development path.
More information can be obtained on www.xceleron.com
About Servier Servier is a privately-owned company, established in 1954 by its founder and current Chairman, Jacques Servier, M.D. Servier allocates approximately 25% of its turnover to Research and Development. Its main therapeutic products used to treat diabetes, cardiovascular disease, neuropsychiatric disorders, cancer, and bone and joint diseases. In the past 18 months Servier has been able to file for registration three innovative pharmaceutical specialties in the field of osteoporosis, cardiovascular diseases and treatment of depression and two of them have already been accepted by EMEA.
For further information:
Xceleron Ltd Prof. Colin Garner, CEO Jeremy Hague, European Business Development Manager Tel: +44 (0) 1904 561561 or visit www.xceleron.com
Posted under Collaborations, Europe, Reports, Research Projects | No Comments
Beyond the Blockbuster Drug: Strategies for nichebuster drugs, targeted therapies and personalized medicine
Last Updated on Tuesday, 15 November 2005 12:37 Written by admin Tuesday, 15 November 2005 12:37
The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital. As a result competitive pressures and falling R&D productivity will instigate a new pharmaceutical model that replaces the unsustainable blockbuster model; personalized medicine and the “nichebuster”.
This report, Beyond the Blockbuster Drug: Strategies for nichebuster drugs, targeted therapies and personalized medicine, examines targeted therapies and targeted drug delivery strategies as alternative investment options for pharmaceutical companies, in the face of declining returns and slow growth in the blockbuster market. This report’s strategic insight is also supported by in-depth interviews with thought leaders from the pharmaceutical industry, providing you with their insight into how tomorrow’s pharmaceutical business model will develop.
This report analyzes the niche pharmaceutical sectors with the greatest potential for profit and future growth. Harness the technological advances in personalized medicine and be part of the “nichebuster” revolution set to drive market growth and produce the market leading drugs of tomorrow.
THE ANSWERS TO YOUR QUESTIONS
In 2006, which blockbuster drugs will be exposed to patent expiration to the value of US$17bn?
What are the key factors slowing blockbuster market growth?
What is the ‘nichebuster’ model and how will it fit into the future landscape of the industry?
How is personalized medicine set to transform the future of the pharmaceutical industry?
Which sectors are currently driving growth for targeted therapies?
Which technologies will produce an explosion of poorly validated targets that may actually increase the rate of compound attrition and the costs of R&D?
What roles will alliances and partnering play in the development of the pharmaceutical sector beyond the blockbuster model?
KEY FINDINGS
From 2005 to 2008, total blockbuster sales are forecast to demonstrate a CAGR of only 1.6% compared with the 9% forecast for the period 2002 to 2005.
In order to grow by 10%, today’s big pharmaceutical companies would need to launch two or three new blockbusters per year.
Alliances and licensing will be increasingly critical to ‘BigPharma´s’ ability to access innovation in novel areas of science, new products in different therapeutic areas, and replacement compounds for late life-cycle drugs.
Technologies such as genomics and proteomics have produced an explosion of new poorly validated targets that may actually increase the rate of compound attrition and the costs of R&D.
Total pharmaceutical R&D outsourcing is expected to grow at a compound annual growth rate (CAGR) of 11-12% from its 2003 level of $7.9 billion, compared to anticipated growth in global R&D spending of only 9.6%.
REASONS TO PURCHASE
Understand how the new ‘nichebuster’ model will revolutionize the pharmaceutical sector and which new growth opportunities this model will promote.
Harness the new era of personalized medicine guided by advances in biotechnology and genetic engineering, and take advantage of the larger opportunities multiple specialist disease areas offer.
Analyze how leading players, such as Novartis and Roche, are using targeted therapies and R&D partnerships for faster growth and benchmark your portfolio growth strategy accordingly.
Evaluate new drug delivery technologies, advances in proteomics and pharmacogenomics set to transform the pharmaceutical sector and identify which technological developments your company can exploit to gain a competitive edge in the market.
Secure your frontline position in the future of the pharmaceutical industry by adapting your product portfolio to meet the healthcare needs of tomorrow.
Posted under North America, Reports | No Comments